EQ/T.Rowe Price Health Sciences Portfolio is a registered fund series of EQ Advisors Trust (series S000062644). Net assets $159.0M as of 2026-03-31.
Showing 15 of 179 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Eli Lilly & Co. | — | $16.2M | 1019.54% |
| Thermo Fisher Scientific, Inc. | — | $6.6M | 412.66% |
| Intuitive Surgical, Inc. | — | $5.9M | 371.07% |
| Stryker Corp. | — | $5.6M | 353.34% |
| Merck & Co., Inc. | — | $5.5M | 348.07% |
| AstraZeneca plc | — | $5.1M | 320.82% |
| UnitedHealth Group, Inc. | — | $5.0M | 311.45% |
| Argenx SE | — | $4.8M | 303.89% |
| AbbVie, Inc. | — | $4.6M | 291.04% |
| Regeneron Pharmaceuticals, Inc. | — | $4.3M | 271.37% |
| Gilead Sciences, Inc. | — | $4.2M | 266.87% |
| Johnson & Johnson | — | $3.9M | 248.12% |
| Vertex Pharmaceuticals, Inc. | — | $3.9M | 247.32% |
| Danaher Corp. | — | $3.3M | 208.24% |
| Alnylam Pharmaceuticals, Inc. | — | $2.7M | 168.52% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $159.0M |
| 2025-12-31 | $176.2M |
| 2025-09-30 | $158.1M |
| 2025-06-30 | $152.8M |
| 2025-03-31 | $159.9M |
| 2024-12-31 | $164.3M |
| 2024-09-30 | $188.7M |
| 2024-06-30 | $185.1M |